The anonymous community for clinical research professionals. Verified with a work email, posted under a pseudonym.
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
Most trials miss their enrollment targets, many sites enroll no one, and the delays cost millions a day. The numbers behind the crisis, and why they are a job story.
Read the piece →
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
Built from a merger, taken private by a private-equity consortium in 2023, and marked by staff for layoffs ever since. The facts of the ownership, and what its people report.
Read the piece →
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
One of the largest CROs, owned by private equity, and the highest-rated of the mega-CROs by its own staff, though the rating is slipping. The facts and the sentiment, kept separate.
Read the piece →
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
A founder-led, vertically integrated CRO growing fast on paper, and carrying the lowest employee ratings of any major CRO. The facts, the sentiment, and the gap between them.
Read the piece →
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
Every conference says trials are going remote. The registry data says decentralization is real but early, concentrated in the wrong places, and reshaping the CRA role rather than ending it.
Read the piece →
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
We pulled every major CRO's employee rating on the same day. The rankings are worth seeing, but the identical complaint running through all of them matters more.
Read the piece →
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
The industry consolidated into a handful of giants through a decade of megadeals. The history is public, and so is the pattern of what happens to staff when the deals close.
Read the piece →
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
Venture money and IPOs decide how many trials start, which decides CRO bookings, which decides hiring. Following the funding is following your own job security upstream.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
What AI in clinical research actually does in 2026: real workflows, failure rates, FDA and EMA rules, and job impact, written for people who work in trials.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
The violations behind clinical warning letters are strikingly consistent year after year. The recurring citations, with real recent examples, and what they say about the work.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
The fastest-growing CRO in the group posted a book-to-bill below 1.0, and the market punished it. A lesson in why bookings matter more than the quarter you are in.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
The largest CRO on earth is carrying a record backlog and a steady book. A look at what that scale actually signals for hiring, and what it hides.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
A quarter of FDA-inspected sponsors draw a citation, and the top finding is failing to monitor trials properly. Read as a labor signal, that is an argument about CRA headcount.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
The strongest book-to-bill in the CRO group came with flat revenue and an accounting change. A worked example in reading a headline number the careful way.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
The visa filings name the employer on every record. Sorting the clinical research roles by sponsor shows which CROs and sponsors reach overseas to staff the quantitative bench.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
Spun off from Labcorp and still posting GAAP losses, Fortrea is booking above 1.1 for the third straight quarter. The bull case, and the caveat, for the people who work there.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
Five public CROs, five book-to-bill ratios, one uneven picture. What the latest quarter's bookings say about where clinical research demand is actually heading.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
Most of the big CROs are booking more work, yet cost-cutting and restructuring are running at the same time. The gap between a recovering book and a frozen headcount, explained.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
The public registry records every trial that gets killed, and why. We read the reasons across thousands of terminated industry trials. Enrollment is the number one killer, and that is a worker story.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
Half a million public trial records, and the CROs that do the work are almost invisible in them. The same transparency gap that hides layoffs hides who actually runs your industry.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
Not all phases fail at the same rate. The registry shows Phase 2 kills trials more often than any other, and it is also the most common phase. What that means for where you sit.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
Analysts keep saying pharma R&D spending is slow. The trial registry lets you see it directly. Industry trial starts peaked in 2021 and have run below that ever since.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
By recruiting-trial count, China sits second only to the United States and far ahead of everyone else in Europe. Where trial sites go, monitoring work and wage pressure follow.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
Thermo Fisher owns one of the largest clinical CROs. Its public layoff record runs to 47 filings, and almost none of them are the CRO. A lesson in reading a conglomerate.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
One of the few drug-development names with a thick public layoff record. Sixteen filings since 2014 show where the preclinical and manufacturing cuts are landing, and why the pattern matters.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
The big clinical CROs barely appear in the public WARN record, even in a soft market. That absence is not good news. It is a measurement problem, and here is what it hides.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
The public layoff filings have addresses. Plot them and the cuts cluster in a few places. Where the drug-development pain is landing, and what the map does and does not show.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
A recurring sweep of the public layoff filings that touch clinical research. This edition: what the record shows in mid-2026, and what it conspicuously does not.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
The world's second-largest CRO, built by a $12 billion acquisition, now navigating slow pharma spending. The public numbers, and the questions worth asking before you sign.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
OpenAI called 2026 its year of science, shipped a life sciences model, and signed Novo Nordisk and Eli Lilly. When the news broke, IQVIA and Charles River shares fell. That reaction is the story for the people who work there.
Read the piece →
Editorial · Industry talk · 45d · Open Label Desk [Editorial]
The AI company behind Claude now sells a research workbench, runs its own drug program, and lists Medidata and ClinicalTrials.gov among its connectors. What that means for the people who run trials.
Read the piece →
Poll · Industry talk · 48d · Open Label Desk [Editorial]
Career growth, tooling, and how the function is treated, not just pay. One vote each, results show after you vote.
0 votes · vote to see results
Editorial · Industry talk · 48d · Open Label Desk [Editorial]
A pattern from dozens of conversations with CRO staff: the people who get promoted are the ones sponsors see in meetings, not the ones who quietly keep the database clean. If true, the career advice changes completely. Visibility work stops being vanity and becomes strategy. Editorial perspective, not insider testimony. The poll below is the real data. Has this been true where you work?
0 votes · vote to see results
Editorial · Industry talk · 49d · Open Label Desk [Editorial]
Vendor decks promise automated submissions. The papers programmers write themselves describe something narrower, and they are missing one thing: numbers.
Read the piece →
Question · Industry talk · 49d · Open Label Desk [Editorial]
Every year the conference decks say the CRA role is transforming and half of source verification is going remote. Travel percentages in job ads say otherwise. Where is remote monitoring actually real in your world, and where is it still a slide?
Question · Industry talk · 50d · Open Label Desk [Editorial]
Implementation is where guidance becomes workload. The question for the room: did your company run working sessions with updated SOPs and time to absorb them, or a recorded webinar and a quiz? No names needed; the point is calibrating whether your experience is typical.
Editorial · Industry talk · 55d · Open Label Desk [Editorial]
CRA turnover has run between roughly 22 and 30 percent in recent years. What that number does to studies, sites, and your leverage.
Read the piece →
Editorial · Industry talk · 56d · Open Label Desk [Editorial]
US employers above a certain size must file advance notice of mass layoffs. Those WARN filings are public, and almost nobody in this industry reads them.
Read the piece →
Editorial · Industry talk · 58d · Open Label Desk [Editorial]
The largest CRO on earth, by the public numbers, and the questions worth asking before you sign there.
Read the piece →